Historical Valuation
Calidi Biotherapeutics Inc (CLDI) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.27. The fair price of Calidi Biotherapeutics Inc (CLDI) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：1.05
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Calidi Biotherapeutics Inc (CLDI) has a current Price-to-Book (P/B) ratio of 1.20. Compared to its 3-year average P/B ratio of -12.54 , the current P/B ratio is approximately -109.59% higher. Relative to its 5-year average P/B ratio of -21.66, the current P/B ratio is about -105.56% higher. Calidi Biotherapeutics Inc (CLDI) has a Forward Free Cash Flow (FCF) yield of approximately -252.09%. Compared to its 3-year average FCF yield of -142.50%, the current FCF yield is approximately 76.91% lower. Relative to its 5-year average FCF yield of -108.37% , the current FCF yield is about 132.62% lower.
Competitors Valuation Multiple
AI Analysis
The average P/S ratio for CLDI competitors is 0.00, providing a benchmark for relative valuation. Calidi Biotherapeutics Inc Corp (CLDI.A) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis
1Y
3Y
5Y
Market capitalization of CLDI increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CLDI in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CLDI currently overvalued or undervalued?
Calidi Biotherapeutics Inc (CLDI) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.27. The fair price of Calidi Biotherapeutics Inc (CLDI) is between to according to relative valuation methord.
What is Calidi Biotherapeutics Inc (CLDI) fair value?
CLDI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Calidi Biotherapeutics Inc (CLDI) is between to according to relative valuation methord.
How does CLDI's valuation metrics compare to the industry average?
The average P/S ratio for CLDI's competitors is 0.00, providing a benchmark for relative valuation. Calidi Biotherapeutics Inc Corp (CLDI) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Calidi Biotherapeutics Inc (CLDI) as of Jan 17 2026?
As of Jan 17 2026, Calidi Biotherapeutics Inc (CLDI) has a P/B ratio of 1.20. This indicates that the market values CLDI at 1.20 times its book value.
What is the current FCF Yield for Calidi Biotherapeutics Inc (CLDI) as of Jan 17 2026?
As of Jan 17 2026, Calidi Biotherapeutics Inc (CLDI) has a FCF Yield of -252.09%. This means that for every dollar of Calidi Biotherapeutics Inc’s market capitalization, the company generates -252.09 cents in free cash flow.
What is the current Forward P/E ratio for Calidi Biotherapeutics Inc (CLDI) as of Jan 17 2026?
As of Jan 17 2026, Calidi Biotherapeutics Inc (CLDI) has a Forward P/E ratio of -0.20. This means the market is willing to pay $-0.20 for every dollar of Calidi Biotherapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Calidi Biotherapeutics Inc (CLDI) as of Jan 17 2026?
As of Jan 17 2026, Calidi Biotherapeutics Inc (CLDI) has a Forward P/S ratio of 0.00. This means the market is valuing CLDI at $0.00 for every dollar of expected revenue over the next 12 months.